Transcutaneous vaccination with virus-like particles

Vaccine
Sarah L YoungMargaret A Baird

Abstract

Virus-like particles (VLP) are inert, empty capsids of viruses, which contain no DNA/RNA from the virus itself. However they retain the structure of a virus and they can be engineered to have antigens attached. We have constructed VLP, derived from Rabbit hemorrhagic disease virus, and shown they are highly immunogenic. We tested the capacity of these engineered VLP to induce immune responses when they are administered to mice via the transcutaneous route. This route of vaccination is important, in order to generate mucosal protection. Our data showed that VLP are taken up by dendritic cells (DC), antigen-presenting cells that are essential to initiate acquired immune responses. The VLP induced an increase in expression of CD40, CD80 and CD86 but required an adjuvant, CpG DNA oligo-deoxy nucleotides (ODN) motifs, to enhance these responses. In vivo testing has also shown that the VLP, when wiped on to the skin in conjunction with immunostimulatory CpG, induce Ag-specific immune responses, typified by high levels of IFN-gamma and IgG1.

References

Feb 9, 2000·Archives of Virology·H S NageshaA D Hyatt
Sep 21, 2000·Journal of Reproductive Immunology·K W Beagley, P Timms
Nov 22, 2002·The New England Journal of Medicine·Laura A KoutskyUNKNOWN Proof of Principle Study Investigators
Apr 25, 2003·International Reviews of Immunology·Kathleen A Kelly
Oct 15, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·A C HesselingR M Warren
Oct 31, 2003·Expert Reviews in Molecular Medicine·Robert J SalmondNeil A Williams
Jun 15, 2004·Vaccine·Charalambos D PartidosSylviane Muller
Jul 9, 2004·Nature·Marianne Boes, Hidde L Ploegh
Sep 24, 2004·Scandinavian Journal of Immunology·M BairdG Buchan
Jul 20, 2005·Vaccine·Anke HuckriedeJan Wilschut

❮ Previous
Next ❯

Citations

Feb 14, 2012·Veterinary Research·Joana AbrantesPedro J Esteves
Apr 2, 2008·Expert Review of Vaccines·Jeremy WalesMarc Feldmann
Apr 22, 2011·Expert Review of Vaccines·Ramadevi Raghunandan
Sep 28, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Suzanne M BalJoke A Bouwstra
Mar 6, 2007·Vaccine·J C Aguilar, E G Rodríguez
Oct 12, 2015·Applied Microbiology and Biotechnology·Dan YanShi-Qi Sun
Jun 5, 2007·Biotechnology and Bioengineering·Matthew PeaceyVernon K Ward
Oct 1, 2011·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·S M SivakumarN Sukumaran
Jan 1, 2010·Annual Review of Chemical and Biomolecular Engineering·Pankaj Karande, Samir Mitragotri
Oct 14, 2017·Archives of Pharmacal Research·Rakesh BastolaSangkil Lee
Aug 16, 2017·Journal for Immunotherapy of Cancer·Braeden DonaldsonSarah L Young
Jul 14, 2020·Journal of Cellular Physiology·Zhongtao FengJafar Hajavi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.